Medical/Pharmaceuticals

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:12 2897

China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up

HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...

2021-09-09 18:06 3064

B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System

TOKYO, Sept. 9, 2021 /PRNewswire/ -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at its factory, for a compact proton cancer therapy system under development, and confirmed the generation of a magnetic field. That means a major ...

2021-09-09 15:00 1964

Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting

BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Ass...

2021-09-09 15:00 3339

Nanoform technology delivers successful results for Herantis CDNF drug candidate

HELSINKI, Sept. 9, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc ("Herantis"), focusing on disease modifying therapies for debilitating neurodegenerative diseases based on the natural body protein CDNF (Cerebr...

2021-09-09 14:04 2082

Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility

SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...

2021-09-09 11:40 4529

WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer

SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhi...

2021-09-09 08:26 7122

CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC WCLC 2021

SUZHOU, China, Sept. 9, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced that efficacy and safety data from a...

2021-09-09 08:00 4737

HaemaLogiX raises $10 million to advance multiple myeloma treatments

* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...

2021-09-09 05:00 2818

Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met

SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of  pyrilutamide ("KX-8...

2021-09-08 22:13 4974

Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza

-- First participants enrolled in Phase 1 clinical trial of combination NanoFlu™/NVX–CoV2373 vaccine with Matrix-M™ adjuvant -- Phase 1/2 study will evaluate immunogenicity and safety GAITHERSBURG, Md., Sept. 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated...

2021-09-08 20:30 6692

Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of brea...

2021-09-08 20:08 4973

The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare

Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...

2021-09-08 19:00 4323

HICOOL 2021 Global Entrepreneur Summit

BEIJING, Sept. 8, 2021 /PRNewswire/ -- HICOOL 2021 Global Entrepreneur Summit, a global event for entrepreneurs, will be held inBeijing on September 10-11, 2021, at the Beijing International Exhibition Center (New Venue) in Shunyi, Beijing, with the theme "Connect Startups Worldwide, Innovate Bei...

2021-09-08 16:30 2435

Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets Granted Drug Certificate

SHIJIAZHUANG, China, Sept. 8, 2021 /PRNewswire/ -- Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate byChina's National Medical Products Administration (NMPA). With the functions of reinforcing kidney, n...

2021-09-08 12:28 3369

Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors

NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple ...

2021-09-08 11:04 3154

Bactiguard appoints new CEO

The Board of Bactiguard Holding AB (publ) has today appointed Anders Göransson as the new CEO. Anders has extensive experience from consulting within McKinsey and has held several senior positions in Amgen, most recently as Head of Innovation Europe. Anders will start his employment in Bactiguard...

2021-09-08 09:51 3123

NCCN Shares Latest Expert Recommendations for Prostate Cancer in Spanish and Portuguese

PLYMOUTH MEETING, Pa., Sept. 8, 2021 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit alliance of leading cancer centers in the United States—announces recently-updated versions of evidence- and expert consensus-based guidelines for treating prostate cancer,translate...

2021-09-08 09:37 2258

Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver dise...

2021-09-08 08:30 4455

Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-09-08 08:00 8360
1 ... 628629630631632633634 ... 647